Apricoxib

N/A

Report date: 2023/09/04 20:08:23
NME

Base Information

Drug NameApricoxib
Drug Alias NameTP1001 programme帕瑞昔布Apricoxibum阿利昔布Capoxigem +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclooxygenase-2 inhibitors
TargetsCyclooxygenase-2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTragara Pharmaceuticals IncUniversity Of Maryland, Baltimore
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsPancreatic Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG